Phylonix Pharmaceuticals, Inc.
Phylonix has developed general and organ specific assays such as apoptosis and angiogenesis. Effect of drug treatment can be observed visually in transparent zebrafish embryos, and quantitative endpoint assays can be performed using microplate readers, in a format similar to cell based assays. Because in vivo zebrafish assays are more informative than cell based assays, the Company’s drug screening system can streamline the pre-clinical drug development process. In addition to drug screening, the Company also uses the zebrafish-based assays for target validation.Back to list